Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Takes A Back Seat to No One When it Comes to Drug Safety

This article was originally published in RPM Report

Executive Summary

Amgen, J&J and a host of supporters urged CMS to wait until FDA completes its safety review of EPO before acting to limit coverage. CMS is having none of it.
Advertisement

Related Content

Straight Talk About Cancer Drug Coverage
Straight Talk About Cancer Drug Coverage
Avoiding Another EPO: Amgen's Nplate Has FDA Restrictions, But May Escape Medicare Controls
Access and Evidence: Implications of the EPO Safety Debate (Part 2)
FDA's Unlikely Defenders

Topics

Advertisement
UsernamePublicRestriction

Register

PS080338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel